Inflammatory Bowel Disease
Seres Therapeutics’ development candidate, SER-287, is an investigational oral microbiome therapeutic for the treatment of Inflammatory Bowel Disease (IBD).
Ulcerative Colitis, a form of Inflammatory Bowel Disease (IBD) is a serious chronic condition affecting approximately 700,000 individuals in the United States. The disease results in inflammation of the colon and rectum and can result in debilitating symptoms, including abdominal pain, bowel urgency, and diarrhea.
SER-287 is an oral therapy being developed as a potential treatment for UC. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease and the first in an indication outside of infectious disease. Seres reported positive results of its Phase 1b study of SER-287 in patients with UC. Future development in other forms of IBD are under consideration.
Current medical therapies remain suboptimal for the treatment of UC with many patients not responding to current therapy. SER-287 represents a novel and unique method to treat UC, which, rather than suppressing the immune system, may reduce the triggers of immune activation.
In addition, published clinical reports furthermore demonstrate that modulation of the microbiome through repetitive fecal microbiota transplants lead to clinical response in certain UC patients. 1,2
SER-287 is an oral capsule developed using Seres’ proprietary microbiome therapeutics platform. It is a biologically-sourced therapeutic candidate comprised of a complex and diverse bacterial spore ecology. In addition to SER-287, Seres’ development pipeline includes SER-301, a rationally designed, synthetic product comprised of in vitro cultured bacterial species for development in UC and other chronic gastrointestinal disorders with high unmet medical need.
Click here to learn more about the SER-287 clinical trial.
1. Moayyedi, P, et al, Gastroenterology, 2015.
2. Paramsothy S. et al, The Lancet, 2017.